Back to search results

Palliative Care Approaches for Acute Myeloid Leukemia (AML)

This study is comparing two ways of providing palliative care to patients with Acute Myeloid Leukemia (AML), a type of blood cancer. One approach is "Specialty Palliative Care," where both cancer doctors and palliative care specialists (doctors focused on comfort and quality of life) work together during your hospital stay. The other is "Primary Palliative Care," where your cancer doctors receive special training in palliative care. The study wants to see if primary palliative care can improve your quality of life, symptoms, mood, and how you cope with AML, as much as specialty palliative care. You might be able to join if you are 18 to 120 years old, have high-risk AML (like a new diagnosis if you're over 60, or if your AML has come back or is hard to treat), and are starting chemotherapy. The main goal is to measure your quality of life over 12 weeks.

Study design
This interventional study plans to enroll 2300 participants. It compares two different approaches to palliative care for patients with AML.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your quality of life will be measured for over 12 weeks after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05237258

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Recruiting
NAAges 18+InterventionalSupportive care
Massachusetts General Hospital
~2,300 participants
Updated 2025-07-25 on ClinicalTrials.gov
What's tested:Specialty Palliative CarePrimary Palliative Care

At a glance

Recruiting sites
20 of 20 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Quality of Life (QOL)
Measured over Over 12 weeks

Conditions

Relapsed Adult AML
Primary Refractory Acute Myeloid Leukemia
High Risk Acute Myeloid Leukemia

Explore related trials

Acute Myeloid Leukemia

Where it's being run

20 sites across 17 states
Florida2
Massachusetts2
North Carolina2
Alabama1
California1
Colorado1
Georgia1
Illinois1

Study leadership

  • Areej El-Jawahri, MD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital
  • Jennifer Temel, MD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital

Who to contact

Areej El-Jawahri, MD
[email protected]
617-724-4000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Hospitalized patients (age ≥ 18 years) with high-risk AML defined as:
Patients with new diagnosis ≥ 60 years of age
An antecedent hematologic disorder
Therapy related-disease
Relapsed or primary refractory AML
Within five business days of initiating therapy with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen requiring prolonged hospitalization; or b) hypomethylating agents +/- additional agents or modification of this regimen on a clinical trial.
Adult (≥18 years) relative or friend of a participating patient who the patient identifies as living with or has in-person contact with them at least twice per week.

Exclusion

Patients with a diagnosis of acute promyelocytic leukemia (APML)
Patients with AML receiving supportive care alone
Patients with psychiatric or cognitive conditions which the treating clinicians believe prohibits informed consent or compliance with study procedures
Patients seen by a palliative care clinician (MD, DO, APP) during two previous hospitalizations in the six months prior to enrollment
Patients expected to be discharged within 2 days

What this trial measures

  • Quality of Life (QOL)Over 12 weeks

    Establish that primary palliative care is non-inferior to specialty palliative care in patient-reported quality of life (QOL) as measured by the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leukemia) over 12 weeks. Higher scores on FACT-Leukemia (range 0-176) indicate a better QOL.